current developments in interop analysis

55
Cambridge Polymer Group, Inc. Testing, Consultation, and Instrumentation for Polymeric Materials Assessing the Cleanliness of Medical Devices Stephen Spiegelberg Presented at the 3 rd Annual Orthopaedic Manufacturing & Technology Exposition and Conference (OMTEC 2007), June 20-21, 2007, Chicago, IL.

Upload: others

Post on 15-Nov-2021

7 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Current Developments in Interop Analysis

CambridgePolymer Group, Inc.

Testing, Consultation, and Instrumentation for Polymeric Materials

Assessing the Cleanliness of Medical Devices

Stephen Spiegelberg

Presented at the 3rd Annual Orthopaedic Manufacturing & Technology Exposition and Conference (OMTEC 2007), June

20-21, 2007, Chicago, IL.

Page 2: Current Developments in Interop Analysis

Background of Cambridge Polymer Group

• Contract research company formed in 1996• Core competencies

– polymer R&D– test methodology development– instrumentation design

• Biomedical community– bone cement– crosslinked polyethylene– spine– eye– vascular– product recalls– cleanliness of medical devices

Page 3: Current Developments in Interop Analysis

• Sterile: live microorganisms content is below acceptable levels– Bacteria, yeast, fungi, molds, viruses– Sterility Assurance Limit (SAL): probability that an implant will

remain nonsterile following sterilization • 10-6 (one in a million)

• Clean: non-live residue content is below acceptable levels– Pyrogens – dead but deadly– Chemicals– Particulate matter

Sterile is not the same as Clean

Page 4: Current Developments in Interop Analysis

Sterile is not the same as clean

Glutaraldehyde

Ethylene oxide

Steam/Dry Heat*

Plasma

Ionizing radiation*

Methods of Sterilization

Detergent Wash

Alcohol Wash

Acid Passivation

Air blasting

High pressure rinses

Sonication

Methods of Cleaning

*issues with polymeric devices

Page 5: Current Developments in Interop Analysis

Case Study I

• In 2000, Sulzer Orthopedics noticed higher than normal revision surgeries on their InterOp Acetabular Shell

• High failure rate in isolated manufacturing group

Explanted hip components showed little tissue ingrowth into the porous titanium backing, even after 11 months of in vivo use.

Spiegelberg, Deluzio, Muratoglu, Trans Orthopedic Research Society, 2003

Page 6: Current Developments in Interop Analysis

InterOp Acetabular ShellCementless fixation: relies on osseointegration in porous titanium structure

Page 7: Current Developments in Interop Analysis

What Happened?

Independent Research Team

Pathologists Manufacturing Experts Analytical Labs

Try to identify type of residue in order to determine best analytical technique

Design sample preparation procedure to extract and quantify residue

Validate extraction and analysis technique

Determine resolution levels

Believed to be related to a manufacturing residue

Page 8: Current Developments in Interop Analysis

Preliminary Information

• Suspected that a residue was on implants

• Introduction believed to be from machining lubricants

• Received sample lubricants from manufacturer

Page 9: Current Developments in Interop Analysis

Protocols

• Extract residue from component

– solvent selection

• Analyze mass of residue with quantified technique

• Identify composition

• Look for trends with manufacturing

Page 10: Current Developments in Interop Analysis

Solvent Selection

-1

0

1

2

3

4

5

400900140019002400290034003900

wavenumber [cm-1]

abso

rban

ce [A

.U.]

oilCarbon tetrachlorideChloroform

Select solvent that does not have an IR absorption band in the region of the target materialGood solvent for target material

C Cl

Cl

Cl

Cl

oil

Carbon tetrachloride

HH

Page 11: Current Developments in Interop Analysis

Extraction Protocol

Protocol on web site: www.campoly.com

Carbon tetrachloride

Sonicate for 1 hour

Rinse component

Concentrate solution(77 C)

Page 12: Current Developments in Interop Analysis

Infra-red Spectroscopy

0

10

/log (1/ )

Transmission T I IAbsorbance A T

==

Beer’s Law: A = αbcα = absorptivity of chemical speciesb = path length of cellc = concentration of chemical species

Used to identify hydrocarbon-based components in residue

C H

Page 13: Current Developments in Interop Analysis

Calibration Curve for Oil

A = 325.27cR2 = 0.9967

0

10

20

30

40

50

60

70

0 0.05 0.1 0.15 0.2 0.25

hydrocarbon concentration [wt.%]

A28

19-2

992

cm-1

Oils A, I, K, F, D

1 mm path lengthAreas baseline-corrected

A = αbc

Page 14: Current Developments in Interop Analysis

Validation Study

Oil Measurement Validation Study

0

5

10

15

20

25

30

35

40

45

1 2 3 4 5 6 7 8 9 10

sample

oil c

onte

nt [m

g]

Applied Oil

0

5

10

15

20

25

30

35

40

45

1 2 3 4 5 6 7 8 9 10

Meas ured Oil C on ten t

Porous titanium test samples coated with known amounts of oilO

il co

nten

t [m

g]

Corrections for hydrocarbons in solvent

Page 15: Current Developments in Interop Analysis

Oil in Shelf-Stored Components

• Examined oil content in over 500 acetabular shells

• Grouped component lots by manufacturing history

Page 16: Current Developments in Interop Analysis

Manufacturing Procedure

Machine titanium

shell

Apply porouscoating

High temperaturesintering

Nitric acidpassivation

Detergentwash&rinse

Group1

Group2

Peg chamfer

Group3

ID turn

Group4

No passivation

Page 17: Current Developments in Interop Analysis

Manufacturing History Analysis

0

10

20

30

40

50

60

70

80

1260000 1280000 1300000 1320000 1340000 1360000 1380000 1400000 1420000 1440000 1460000

Lot Number

Oil

Con

tent

(mg)

Group1Group2Group3Group4

passivation

88% of failures

No statistical dependence of oil content on manufacturing history

no passivation

Page 18: Current Developments in Interop Analysis

Oil Removal by Nitric Acid Passivation

0

10

20

30

40

50

60

70

Control Passivation Only

Res

idua

l Oil

Con

tent

[mg]

A SeriesK SeriesAIK Series

• Nitric acid passivation does not remove measurable quantities of oil

1 hour soak in 27 vol.% nitric acid

Page 19: Current Developments in Interop Analysis

Fluid Absorption Analysis

• CsTi test coupons weighed, then soaked in water/bovine serum

• Determine fluid absorption by weight difference

• Dependence on presence of oil, nitric acid passivation

Page 20: Current Developments in Interop Analysis

Fluid Absorption Analysis

0

0.05

0.1

0.15

0.2

0.25

0.3

0 20 40 60 80 100 120

oil content [mg]

fluid

abs

orpt

ion

[g]

0

0.05

0.1

0.15

0.2

0.25

0.3

tota

l flu

id u

ptak

e [m

l]

Mineral Oil A

0

0.05

0.1

0.15

0.2

0.25

0.3

0 20 40 60 80 100 120

oil content [mg]

fluid

abs

orpt

ion

[g]

0

0.05

0.1

0.15

0.2

0.25

0.3

tota

l flu

id u

ptak

e [m

l]

Mineral Oil A

0

0.05

0.1

0.15

0.2

0.25

0.3

0 20 40 60 80 100 120

oil content [mg]

fluid

abs

orpt

ion

[g]

0

0.05

0.1

0.15

0.2

0.25

0.3

tota

l flu

id u

ptak

e [m

l]

Mineral Oil A

Presence of oil affects fluid absorption only through volumetric meansNo major effects of nitric acid observed

Red symbols: no passivationBlue symbols: nitric acid passivation

Page 21: Current Developments in Interop Analysis

Histopathology of Tissue from 113 InterOp Shells

• Acute and chronic inflammation in periprosthetic tissue, with an abundance of lymphocytes, granulation tissue, neutrophils, and giant cells. Staining was highly positive for IL-1b and Il-6 activity [1].

• Inflammation was found in the capsule as well, and was not therefore relegated to tissue in direct contact with the device.

• Concluded that a substance in the oil, rather than the oil itself, was responsible for the inflammation [1, 2].

1. Campbell, P.M., J; Catelas, I. Examination of Recalled Inter-Op Acetabular Cups for Cause of Failure. in Society for Biomaterials. 2002. Tampa, FL.2. Campbell, P.M., J; Catelas, I. Histopathology of tissues from Inter-Op acetabular sockets. in 48th Annual Meeting of the Orthopaedic Research Society. 2002.

Page 22: Current Developments in Interop Analysis

3 Week Rabbit Study

Tissue response in rabbits injected with Oil I

Tissue response in InterOp patients

Acute Inflammation No Yes

Chronic Inflammation 82.1% Extensive

Eosinophils 96.4% Minimal

Giant Cells 14.3% Abundant

Fibrunous Exudate No Yes

Lipogranuloma 82.1% No

Granulation Tissue No Abundant

Lipid Droplets 46.4% No

Metal No Yes

Other Foreign Body 3.6% Yes

Fibrous Tissue 42.9% Yes

Necrosis 3.6% Yes

Bloebaum, R.D., E.L. Whitaker, J. Szakacs, and A. Hofmann. The tissue response to an injection of gamma sterilized mineral oil in rabbits. in 49th Annual Meeting of the Orthopaedic Research Society. 2003. New Orleans, LA.

Only 2 pathological markers were shared in the two studies

Page 23: Current Developments in Interop Analysis

Nitric Acid + Oil

-0.1

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

10001100120013001400150016001700180019002000

w avenum ber [cm -1]

abso

rban

ce [A

.U.]

residue-top layer (primarily oil)residue-bottom layer (primarily acid)oil A

removed

new

removed

• There is a modest chemical change in the oil with exposure to acid• GC/MS analysis on residues was inconclusive•Cytotoxicity testing on the residues came back negative

Page 24: Current Developments in Interop Analysis

Could Endotoxins be the culprit?• Histopathology of endotoxins produced a similar tissue response as

that observed in the Inter-Op tissue [1].

• Nitric acid passivation can reduce the levels of endotoxins adhered to titanium samples [2].

• Endotoxins were found in the sump water of the machine shop

• Trace amounts could be stationed at the oil-tissue interface, enough to prevent osseointegration

a lipopolysaccharide (LPS) produced from Gram-negative bacteria

1. Greenfield, E.M., Y. Bi, A.A. Ragab, V.M. Goldberg, J.L. Nalepka, and J.M. Seabold, Does endotoxin contribute to aseptic loosening of orthopedic implants? J. Biomed. Mater Res, Part B: Appl. Biomater., 2005. 72B: p. 179-185.2. Merritt, K., S.A. Brown, and V.M. Hitchins. Ability of nitric acid or acetone to inactivate bacterial lipopolysaccharide (LPS). in 28th Annual Meeting Transactions of the Society for Biomaterials. 2002

Page 25: Current Developments in Interop Analysis

Conclusion of Case I Study

• Oil present on all manufactured lots tested, including those with successful outcomes

– Specific manufacturing history associated with failed implants

• Explanation of clinical response

– not related to absolute level of oil

– appears to be related to nitric acid passivation step

• Most likely culprit was an adherent endotoxin that was delivered via the oil, and was not inactivated by nitric acid passivation

Page 26: Current Developments in Interop Analysis

Case Study II: Residue Identification

• What manufacturing residues are introduced?

– Release agents

– Lubricants/coolants

– Polishing compounds

– Cleaning agents

– Particulate debris

– Eluants from packaging

– Chemicals from gloves

• Identification allows the manufacturer to identify and control the source of the residue production

Page 27: Current Developments in Interop Analysis

Further Identification of Residues

Analytical techniques

– FTIR indicates quantity of oil, but not identity

• Sum of all parts

– Soluble residue: Gas Chromatography/Mass Spectroscopy

– Insoluble residue: Energy dispersive spectroscopy (EDS)

Page 28: Current Developments in Interop Analysis

Gas Chromatography/Mass Spec.

liquid phase

carrier gas

injected grouped chemical

chemicals are separated

• species partially dissolves in liquid phase• re-enters gas stream when partial pressure in gas

stream drops

to mass spec

GC Phase: Separates the compounds

Page 29: Current Developments in Interop Analysis

Mass Spectrometer

• Ionizer: Electrons create ions from gas molecules• Analyzer: Filters by mass-to-charge ratio (m/z)• Detector: Measures ion current, proportional to quantity of single

m/z molecules • Good up to around 400-500 g/mole

e-+

+

+

+from GC

ionizerheated filament

analyzer detector

203Ti

205Ti

207Pb

208Pb

mass/chargeio

n cu

rren

t

200 212

Calibrate detector with metallic salts

Identifies the compounds

Page 30: Current Developments in Interop Analysis

GC/MS Analysis of Residues

• Catalogued all compounds that may have come into contact with machined components

• Identified which residue composition was present on component

• Identify what manufacturing step introduces residueRoughing Pump Oil approximatechemical composition concentration %octadecane 1nonadecane 11-hentetracontanol 11-chloro-octadecane 1117-pentatriacontene 17(1-butylhecadecyl)-cyclohexane 191-octadecanethiol 6(2-hexyloctyl)-cyclopentane 9N-methyl-N-[4-[4-methoxyl-1-hexahydropridyl]-2-butynyl]-acetamide 71',4 dihydroxy-2,3' dimethyl-, (-)-[1,2'-binaphthalene]-5,5',8,8'-tetrone 251-docosene 3

*GC/FID: approx. 1-10 ppm

Page 31: Current Developments in Interop Analysis

Insoluble Residue

• Scanning Electron Microscopy

• Energy Dispersive X-ray Spectroscopy (EDS or EDXA)

– Qualitative/semi-quantitative

– particulate matter adhered to carbon tape, then analyzed in Phillips XL-30 FEG SEM.

Page 32: Current Developments in Interop Analysis

EDS System (in-line with SEM)

Energy of X-ray {KeV]

X-ray tube

sampledetector

KL

M

KL

M

X-rayIncident electronor X-ray

ejected electron

0.1-1 wt.% resolution

Page 33: Current Developments in Interop Analysis

EDS Analysis of Extracted Residue

aluminum

Page 34: Current Developments in Interop Analysis

EDS Analysis of Extracted Residue

silica

titanium vanadium

iron sodium

10 microns

Page 35: Current Developments in Interop Analysis

Conclusions to Case II

• Manufacturers have techniques to identify type of residue

• Source of residue in manufacturing process

Page 36: Current Developments in Interop Analysis

Case Study III: Residue on Explants

• Can we extract and identify manufacturing residues on explanted devices?

• Possibly identify source of implant failure

Page 37: Current Developments in Interop Analysis

Explant Analysis

• Problem: biological tissue are hydrocarbon-based

• Look very similar to hydrocarbon-based manufacturing residues under FTIR

-1

-0.5

0

0.5

1

1.5

2

2.5

3

3.5

4

24002500260027002800290030003100320033003400

wavenum ber [cm -1]

abso

rban

ce [A

.U.]

oillipids

H-C Stretch

O

O

C C

H

H

C

H

H

H

H

H

O

O

C CH

H

CH

H

HH

O

O

C C

H

H

C

H

H

HCH

C

C

H

10

10

10

H

H

C

H

H

HCC

H

H

H 10

triglyceride

mineraloil

Page 38: Current Developments in Interop Analysis

Explant Analysis

• Remove lipids from solution

• Protocol similar to shelf-stored analysis

– Sonication with carbon tetrachloride

– Evaporation

– Filtration

• Isolates manufacturing hydrocarbons from lipids and most other biological residues

– infra-red analysis

Page 39: Current Developments in Interop Analysis

Explant Analysis

0

10

20

30

40

50

60

70

80

90

shell 1 shell 2

oil c

onte

nt [m

g]

Applied amountMeasured amountno filtration

Pre-doped devices extracted in presence of 5 grams of acetabular tissue

Page 40: Current Developments in Interop Analysis

Cadaver Analysis

• Shells were doped with known amounts of oil, then placed in cadavers for 24 hours

• Extraction, then filtration

Page 41: Current Developments in Interop Analysis

Cadaver Analysis

Cadaver Specimens

0

5

10

15

20

25

30

35

40

45

az197 az198 az199 az200 az201

oil c

onte

nt [m

g]

0

500

1000

1500

2000

2500

3000

3500

4000

4500

resi

due

mas

s [m

g]

0

5

10

15

20

25

30

35

40

45

az197 az198 az199 az200 az201

oil c

onte

nt [m

g]

0

500

1000

1500

2000

2500

3000

3500

4000

4500

resi

due

mas

s [m

g]

ir-measurementApplied oilresidue content-gravimetric

0

5

10

15

20

25

30

35

40

45

az197 az198 az199 az200 az201

oil c

onte

nt [m

g]

0

500

1000

1500

2000

2500

3000

3500

4000

4500

resi

due

mas

s [m

g]

ir-measurementApplied oilresidue content-gravimetric

Page 42: Current Developments in Interop Analysis

Identification of Extracted Residue from Explant

• FTIR provides limited information on structure of hydrocarbons– Data provided from labs that show hydrocarbons on all explants

(3000 cm-1)– Immediately conclude that these are manufacturing residues– Presence of carbonyls indicate these are probably fatty acids (1700

cm-1)– Systemic long-chain hydrocarbons(1,2)

• GC/MS identifies specific composition of hydrocarbons

1. Liber, A.F. and H.G. Rose, Saturated hydrocarbons in follicular lipidosis of the spleen. Arch. Path., 1967. 83: p. 116-122.2. Rose, H.G. and A.F. Liber, Accumulation of saturated hydrocarbons in human spleens. J. Lab. & Clin. Med., 1966. 68(3): p. 475-483.

Page 43: Current Developments in Interop Analysis

GC/MS on Explant Residues

Fenclofenac: non-steroidal anti- inflammatory drug

Nitrazepam: sleep medication

Tranylcypromine: is a non-hydrazine monoamine oxidase inhibitor, an antidepressant and antimanic (brand name Parnate)

Tricosene

Page 44: Current Developments in Interop Analysis

Elemental Analysis of Explants

• Manufacturing residue and tissue analysis directly on explant

• Scanning electron microscopy/Energy dispersive spectroscopy

• No damage to explant (non-destructive)

Page 45: Current Developments in Interop Analysis

Elemental Analysis of Explants

Page 46: Current Developments in Interop Analysis

Case III: Explant Analysis Summary

• Validated techniques to quantify manufacturing hydrocarbon content

• Residue composition can be analyzed with GC/MS

• Surface residue can be analyzed directly on devices

• Tissue composition can be identified (elements)

Page 47: Current Developments in Interop Analysis

Case Study IV: Other Sources of Residues

• Manufacturer trying to identify all possible source of possible contamination on components

• Determine residues from

– gloves

– packaging

Page 48: Current Developments in Interop Analysis

Gloves Analysis• Gloves were sonicated in carbon tetrachloride, then analyzed

with GC/MS

Vinyl gloves approximate component concentration % phthalic anhydride 1 bis (2-ethylhexyl) phthalate 80 1,2-benxenedicarboxylic acid, diisononyl ester 5 didecyl phthalate 4 1,2-benxenedicarboxylic acid, isodecyl octyl ester 5 1,2-benxenedicarboxylic acid, bis(1-methylheptyl) ester 3 1,2-benxenedicarboxylic acid, diheptyl ester 1 1,2-benxenedicarboxylic acid, diisodecyl ester 1

Latex Gloves approximate component concentration % pentachloro-cyclopropane 3 benzothiazole 9 N,N-dibutyl-formamide 9 butylated hydrotoluene 6 tetraphenyl-pyrazine 15 trichloro-methanesulfonyl chloride 3 acetic acid, octadecyl ester 24 hexatriacontane 6 tetracosane 12 heneicosane 6 dotriacontane 6

Extracted residue: 190 mg

Extracted residue: 30 mg

Page 49: Current Developments in Interop Analysis

Packaging Analysis

• Examine extractables from biomedical component packaging

• Chemical extractables– solution extraction/FTIR

• Debris generation– Scanning electron microscopy

Page 50: Current Developments in Interop Analysis

Chemical Extractables from Packaging

0

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

1.8

400900140019002400290034003900

w avenum ber [cm -1]

abso

rban

ce [A

.U.]

foam residue

dimethyl ester, dodecanedioic

• GC/MS of residue extracted from a component– Phthalate (plasticizer for PET packaging)– Residue from foam packaging

Page 51: Current Developments in Interop Analysis

Packaging Debris Analysis

Electron micrograph of plastic pouch used to hold metallic implant

Page 52: Current Developments in Interop Analysis

How Clean is Clean Enough?

• Determined by:– Analytical detection limits– Achievable with commercial cleaning

processes– Cost of cleaning

• Not possible to remove all residue– Levels that do not elicit an adverse

biological response• Application area in the body• Size of device

Page 53: Current Developments in Interop Analysis

ASTM Activities• ASTM activities on cleanliness issues of

medical devices (F04.15.17)

– Passed first standard on assessing cleanliness (ASTM F2459)

– WK15532: Guide for Assessment of Contamination and Residues on Medical devices

• Compilation of known assays for residues, including endotoxins

– WK13292: Standard Practice/Guide for Shipping Possibly Infectious Materials, Tissues, and Fluids

Page 54: Current Developments in Interop Analysis

Conclusions

• Acceptable levels?

Good historical success of medical device = acceptable levels of residues

Page 55: Current Developments in Interop Analysis

Acknowledgements

• Dr. Gavin Braithwaite• Dr. Orhun Muratoglu• Denise Saltojanes• Partial funding from Sulzer Orthopedics

Visit our web site www.campoly.com for downloadable application notes and presentations